Trial Profile
A Phase I/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Filgrastim; Methotrexate; Procarbazine; Rituximab
- Indications CNS cancer; Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 06 Jun 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2026.
- 06 Jun 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2026.
- 13 Dec 2022 Results (n=15) in the phase 1b portion of this study were presented at the 64th American Society of Hematology Annual Meeting and Exposition.